Posted by Michael Wonder on 01 Apr 2021
CStone announces China NMPA new drug approval of precision therapy Ayvakit (avapritinib) for the treatment of adults with unresectable or metastatic PDGFRA exon 18 mutant gastro-intestinal stromal tumour
31 March 2021 - Ayvakit is China’s first approved precision therapy for patients with PDGFRA exon 18 mutant gastro-intestinal stromal tumour.
CStone Pharmaceuticals today announces that the National Medical Products Administration of China has approved Ayvakit (avapritinib) tablets for the treatment of adults with unresectable or metastatic gastrointestinal stromal tumour harbouring a PDGFRA exon 18 mutation, including PDGFRA D842V mutations.
